Compare AbbVie Inc (ABBV) vs Dover Corp (DOV) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Dover Corporation (DOV) trades at $211.13, up 0.14% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $2.74, and the company raised its full-year guidance. A dividend increase to $0.525 per share and the acquisition of Cloeren highlight positive corporate actions. Valuation ratios include a P/E of 25.53 and net income margin of 13.48%, reflecting solid profitability.

The outlook for DOV is positive, driven by earnings momentum, raised guidance, and strategic acquisitions. Risks include exposure to manufacturing cycles and macroeconomic volatility. With 19 buy ratings and a consensus price target of $232.33, Wall Street sees upside potential, though investors should monitor execution on growth initiatives and sector headwinds.